Deadliest Cancers Receive Fraction of Federal Funding Compared to Survivable Ones
A new NCI study reveals pancreatic and lung cancers get far less research funding per death than breast and prostate cancers.
Summary
A study published in JAMA Network Open by National Cancer Institute researchers found a stark mismatch between cancer lethality and federal research funding. Small-cell lung cancer and pancreatic cancer — the deadliest cancers by mortality-to-incidence ratio — received just $2,818 and $8,945 in federal funding per death respectively in fiscal year 2025. By contrast, breast and prostate cancers, which have far better survival odds, received $69,800 and $126,992 per death. Researchers argue that funding priorities have historically been shaped by incidence rates, advocacy strength, and philanthropic momentum rather than actual mortality burden. The authors call for a reallocation framework that weights cancer lethality and societal suffering more heavily in funding decisions.
Detailed Summary
Federal cancer research funding in the United States is significantly misaligned with cancer lethality, according to a new study from researchers at the National Cancer Institute published in JAMA Network Open. The analysis raises urgent questions about whether the most dangerous cancers are receiving the scientific attention they deserve — and what that means for patients and longevity outcomes broadly.
The study examined nine cancer types and compared federal funding per death against each cancer's mortality-to-incidence ratio (MIR). Small-cell lung cancer had the highest MIR yet received only $2,818 in federal funding per death. Pancreatic cancer, the second most lethal, received $8,945 per death. Meanwhile, breast cancer received $69,800 and prostate cancer $126,992 per death — despite having the two lowest MIRs among cancers studied.
Researchers identified several structural reasons for this disparity. Historical advocacy efforts, philanthropic networks, and industry investment have disproportionately benefited cancers with higher incidence and better survival profiles. Cancers with limited advocacy infrastructure — like liver and lung cancers — depend more heavily on federal dollars, making funding imbalances especially damaging for research progress in those areas.
Experts not involved in the NCI study echoed these concerns. Cleveland Clinic oncologist Suneel Kamath noted that a separate 10-year analysis found cervical, breast, and melanoma cancers received up to 10 times more per-death funding than lung, colorectal, pancreatic, and liver cancers. He suggested that better-funded research into pancreatic cancer could have accelerated recent KRAS inhibitor breakthroughs by a decade.
For longevity-focused readers, this matters because cancer remains a leading cause of premature death and lost healthspan. Systemic underfunding of the deadliest cancers delays therapeutic breakthroughs that could extend survival for millions. The authors advocate for a mortality-weighted funding framework — a structural shift that could meaningfully accelerate progress against the cancers most likely to cut lives short.
Key Findings
- SCLC received only $2,818 per death in federal funding despite having the highest mortality-to-incidence ratio.
- Breast and prostate cancers received up to 45x more federal funding per death than the deadliest cancers.
- Funding patterns are driven by historical advocacy and incidence, not mortality burden or patient suffering.
- Experts estimate better funding could have accelerated pancreatic cancer breakthroughs by a decade.
- Researchers call for a mortality-weighted federal funding framework to redirect resources to deadliest cancers.
Methodology
This is a news report summarizing a research letter published in JAMA Network Open by NCI investigators. The evidence basis is a cross-sectional analysis of federal cancer funding data for fiscal year 2025 across nine cancer types, supplemented by commentary from an independent oncologist citing a separate 10-year funding study.
Study Limitations
The study covers only nine cancer types and one fiscal year, limiting generalizability. Funding-per-death is a simplified metric that does not account for research complexity, existing knowledge base, or pipeline stage. The full study text was not available; findings are based on a research letter and secondary reporting.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.